Biologic Agents in Rheumatology: Safety Considerations

Rheumatic Disease Clinics of North America

Volumn 32, Issue SUPPL. 1, 2006, Pages 3-10

  LEE, SUSAN J ^a   KAVANAUGH, ARTHUR ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABCIXIMAB; ADALIMUMAB; AGALSIDASE BETA; ALTEPLASE; AZATHIOPRINE; BASILIXIMAB; BECAPLERMIN; BEVACIZUMAB; BIOLOGICAL FACTOR; CETUXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LENERCEPT; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ANAPHYLAXIS; ANEMIA; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BLEEDING; BLOOD CLOTTING TIME; CANCER; CARDIOVASCULAR DISEASE; CELLULITIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; DEEP VEIN THROMBOSIS; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; EDEMA; ELECTROLYTE BLOOD LEVEL; EXTRAPULMONARY TUBERCULOSIS; FEVER; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INCIDENCE; INFECTION; INFUSION REACTION; INJECTION SITE REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEGIONNAIRE DISEASE; LEUKOPENIA; LISTERIOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MILIARY TUBERCULOSIS; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PATIENT MONITORING; PNEUMOCYSTOSIS; PNEUMONIA; POLYURIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; PSORIATIC ARTHRITIS; RASH; REMISSION; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SIDE EFFECT; SOLID TUMOR; STEVENS JOHNSON SYNDROME; STROKE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VERTIGO;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RHEUMATOLOGY;

EID: 34147181648     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(07)70003-0     Document Type: Article

References (130)

1. Kavanaugh A., and Lipsky P. Rheumatoid arthritis. In: Rich R., Fleisher T., Shearer W., Schroeder H., and Kotzin B. (Eds). Clinical Immunology. 2nd ed. (2001), Harcourt Publishers, London 61.1-61.21
2. Fuchs H., Kaye J., Callahan L., et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 16 (1989) 585-591
3. Lee S., Yedla P., and Kavanaugh A. Secondary immune deficiencies associated with biological therapeutics. Curr Allergy Asthma Rep 3 (2003) 389-395
4. Kavanaugh A., and Keystone E. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 21 Suppl 31 (2003) S203-S208
5. van Furth R., van Zwet T., Buisman A., and van Dissel J. Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 170 (1994) 234-237
6. Maini R., and Taylor P. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 51 (2000) 207-229
7. Cunha F., Poole S., Lorenzetti B., and Ferreira S. The pivotal role of tumor necrosis alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107 (1992) 660-669
8. Dinarello C., Cannon J., and Wolff S. Tumor necrosis factor is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 163 (1986) 1433-1450
9. Dayer J., Beutler B., and Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162 (1985) 2163-2168
10. Saklatvala J. Tumor necrosis factor-alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322 (1986) 547-549
11. Colombel J., Loftus E., Tremaine W., et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
12. Anker S., and Coats A. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 85 (2002) 12-30
13. Giles J., Gelber A., Nanda S., et al. TNF inhibitor therapy increases the risk of post-operative orthopedic infections in patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 50 9 Suppl (2004) S660
14. Wolfe F., and Michaud K. Rates and predictors of pneumonia in patients with rheumatoid arthritis: Strong association with corticosteroid therapy [abstract]. Arthritis Rheum 50 9 Suppl (2004) S660
15. Listing J., Strangfeld A., Rau R., et al. Infections in RA patients treated with infliximab or etanercept. Ann Rheum Dis 64 Suppl 111 (2005) 433
16. Hughes L., Criswell L., Beasley T., et al. Genetic risk factors for infection in patients with early rheumatoid arthritis taking etanercept or methotrexate [abstract]. Arthritis Rheum 50 9 Suppl (2004) S243
17. Yocum D., Wolfe F., Rahman M., et al. The safety and efficacy of infliximab in RA: 1-year results of a large, randomized, placebo-controlled trial in patients with various comorbidities and background treatments as encountered in clinical practice [abstract]. Arthritis Rheum 50 9 Suppl (2004) S659
18. Schiff M., Bulpitt K., Weaver A., et al. Safety of combination therapy with rheumatoid arthritis [abstract]. Arthritis Rheum 44 Suppl 9 (2001) S79
19. Genovese M., Cohen S., Moreland L., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50 (2004) 1412-1419
20. Weinblatt M., Combe B., White A., Aranda R., Becker J., and Keystone E. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDS: 1-year results of the ASSURE trial [abstract]. Ann Rheum Dis 64 Suppl 111 (2005) 60
21. Benini J., Ehlers E., and Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 189 (1999) 127-137
22. Kaneko H., Yamada H., Mizuno S., et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation tumor necrosis factor-alpha-deficient mice. Lab Invest 79 (1999) 379-386
23. Lee J., Slifman N., Gershon S., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 46 (2002) 2565-2570
24. Slifman N., Gershon S., Lee J., Edwards E., and Braun M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum 48 (2003) 319-324
25. Warris A., Bjorneklett A., and Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344 (2001) 1099-1100
26. Bergstrom L., Yocum D., Ampel N., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum 50 (2004) 1959-1966
27. Keystone E. Safety of biologic therapies-an update. J Rheumatol 32 Suppl 74 (2005) 8-12
28. Crnkic M., Saxne T., Sjoholm A., Truedsson L., Jonsson G., and Geborek P. Response to pneumococcal vaccination in patients with rheumatoid arthritis treated with TNF-blockers and/or methotrexate. Arthritis Rheum 50 9 Suppl (2004) S658
29. van Vollenhoven R. Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol 22 5 Suppl 35 (2004) S122-S125
30. Mikuls T., and Moreland L. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Safety 26 (2003) 23-32
31. Kavanaugh A., Cush J., and Matteson E. ACR Hotline. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis. Part I. Risk of lymphoma with rheumatoid arthritis and TNF inhibitors. March 2003. Accessed at http://www.rheumatology.org/publications/hotline (July 20, 2005).
32. Brown S., Greene M., Gershon S., Edwards E., and Braun M. Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum 46 (2002) 3151-3158
33. Symmons D., and Silman A. Anti-tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer. Arthritis Rheum 50 (2004) 1703-1706
34. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1740-1751
35. Hyrich K., Silman A., Watson K., and Symmons D. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety. Ann Rheum Dis 63 (2004) 1538-1543
36. Geborek P., Bladstrom A., Turesson C., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
37. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
38. Senaldi G., Yin S., Shaklee C., Piguet P., Mak T., and Ulich T. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1571 (1996) 5022-5026
39. Turner J., Frank A., Brooks J., Marietta P., and Orme I. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 102 (2001) 248-253
40. Rojas M., Oliverier M., Gros P., Barrera L., and Garcia L. TNF-α and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages. J Immunol 162 (1999) 6122-6131
41. Mohan V., Scanga C., Yu K., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infection Immunity 69 (2001) 1847-1855
42. Kavanaugh A., Cush J., and Matteson E. ACR Hotline. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis. Part II. CHF, infection and other safety issues. Aug 2003. Accessed at http://www.rheumatology.org/publications/hotline (July 20, 2005).
43. Cunnane G., Doran M., and Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Prac Res Clin Rheumatol 17 (2003) 345-363
44. Bieber J., and Kavanaugh A. Consideration of the risk and treatment of TB in patients with rheumatoid arthritis receiving biologic treatments. Rheum Dis Clin North Am 30 (2004) 257-270
45. Keane J., Gershon S., Wise R., et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
46. Furst D., Breedveld F., Kalden J., et al. Updated consensus statement of biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 63 Suppl II (2004) ii2-ii12
47. Askling J., Fored C., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
48. Squier C., Goetz A., Wagener M., and Muder R. The anergy panel: An ineffective tool to validate tuberculin skin testing. Am J Infect Control 32 (2004) 243-245
49. Emery P., Panayi G., Symmons D., and Brown G. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: The role of protein energy malnutrition. Ann Rheum Dis 43 (1984) 430-434
50. Gomez-Reino J., Carmona L., Valverde V., Mola E., and Montero M. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
51. Perez J., Kupper H., and Spencer-Green G. Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe. Ann Rheum Dis 64 Suppl 111 (2005) 86
52. Magnano M., Robinson W., and Genovese M. Demyelination and the use of TNF inhibition. Clin Exp Rheumatol 22 5 Suppl 35 (2004) S134-S140
53. Robinson W., Genovese M., and Moreland L. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. Arthritis Rheum 44 (2001) 1977-1983
54. Mohan N., Edwards E., Cupps T., et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 44 (2001) 2862-2869
55. Shakoor N., Michalska M., Harris C., and Block J. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
56. Cairns A., Crockard A., McConnell J., Courtney P., and Bell A. Reduced expression of CD44 on monocytes and neutrophils in SLE: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis 60 (2001) 950-955
57. Debandt M., Vittecoq O., Descamps V., Le Loet X., and Meyer O. Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol 22 (2003) 56-61
58. Wolfe F., Freundlich B., and Straus W. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30 (2003) 36-40
59. Wolfe F., and Michaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116 (2005) 305-311
60. Jacobsson L., Turesson C., Gulfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1213-1218
61. Mann D., McMurray J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
62. Chung E., Packer M., Lo K., Fasanmade A., and Willerson J. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
63. Kwon H., Cote T., Cuffe M., Kramer J., and Braun M. Case reports of heart failure after therapy with tumor necrosis factor antagonist. Ann Intern Med 138 (2003) 807-811
64. Calabrese L., Zein N., and Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: Hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63 Suppl II (2004) ii18-ii24
65. Ohta A., Sekimoto M., Sato M., et al. Indispensable role for TNF-α and IFN-γ at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol 165 (2000) 956-961
66. Parke F., and Reveille J. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51 (2004) 800-804
67. Peterson J., Hsu F., Simkin P., and Wener M. Effect of tumour necrosis factor ∝ antagonist on serum transaminases and vitamin in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
68. Magliocco M., and Gottlieb A. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases. J Am Acad Dermatol 41 (2004) 580-584
69. Oniankitan O., Duvoux C., Challine D., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
70. Holtmann M., Galle P., and Neurath M. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 98 (2003) 504-505
71. Campbell S., and Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13 (2001) 191-192
72. Michel M., Duvoux C., Hezode C., and Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 30 (2003) 1624-1625
73. Ostuni P., Botsios C., Punzi L., Sfriso P., and Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62 (2003) 686-687
74. Wendling D., Auge B., Bettinger D., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64 (2005) 788-789
75. Esteve M., Saro C., Gonzalex-Huix F., Suarez F., Forne M., and Viver J. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
76. Ueno Y., Tanaka S., Shimmed M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 50 (2005) 163-166
77. Garcia-Sanchez M., Gomez-Camacho F., Poyato-Gonzalez A., Iglesias-Flores E., Dios-Vego J., and Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10 (2004) 701-702
78. Zein N., and Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo controlled study. J Hepatol 42 (2005) 315-322
79. Kugathasan S., Levy M., Saeian K., et al. Infliximab retreatment in adults and children with Crohn's disease: Risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 97 (2002) 1408-1414
80. Domm A. A patient's reaction to infliximab. Ann Allergy, Asthma, Immunol 90 (2003) 298-301
81. Soykan I., Ertan C., and Ozden A. Severe anaphylactic reaction to infliximab: Report of a case. Am J Gastroenterol 95 (2000) 2395-2396
82. Wasserman M., Weber D., Guthrie J., Bykerk V., Lee P., and Keystone E. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, anti-histamine pre-treatment, & infusion number. J Rheumatol 31 (2004) 1912-1917
83. Baert F., Noman M., Verneire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
84. Sands B., Anderson F., Bernstein C., et al. Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med 350 (2004) 876-885
85. Sandborn W., Hanauer S., Loftus Jr. E., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99 (2004) 1984-1989
86. Papadakis K., Shaye O., Vasiliauskas E., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100 (2005) 75-79
87. Moreland L., Cohen S., Baumgartner S., et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 28 (2001) 1238-1244
88. Zeltser R., Valle L., Tanck C., Holyst M., Ritchlin C., and Gaspari A. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept. Arch Dermatol 137 (2001) 893-899
89. Brandt J., Listing J., Haibel H., et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44 (2005) 342-348
90. Choy E., and Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
91. Hoffman H., Rosengren S., Boyle D., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 (2004) 1779-1785
92. Hawkins P., Lachmann J., Aganna E., and McDermott M. Spectrum of clinical features in Muckle-Wells Syndrome and response to anakinra. Arthritis Rheum 50 (2004) 607-612
93. Bresnihan B., and Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin N Am 29 (2003) 185-202
94. Fleishmann R. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra) in patients with rheumatoid arthritis and comparison to anti-TNF-α agents. Clin Exp Rheumatol 20 Suppl 27 (2002) S35-S41
95. Leandro M., Edwards J., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61 (2002) 883-888
96. Panayi G. B cell-directed therapy in rheumatoid arthritis-clinical experience. J Rheumatol 32 Suppl 73 (2005) 19-24
97. Chambers S., and Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14 (2005) 210-214
98. Edwards J., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
99. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 46 (2002) 2029-2033
100. Looney R., Anolik J., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis Rheum 50 (2004) 2580-2589
101. Grillo-Lopez A., White C., Varns C., et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26 suppl 14 (1999) 66-73
102. Maloney D. Preclinical and phase I and II trials of rituximab. Semin Oncol 26 suppl 14 (1999) 74-78
103. Keogh K., Wylam M., Stone J., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 5291 (2005) 262-268
104. Gonzalez-Stawinski G., Yu P., Love S., Parker W., and Davis Jr. R. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 98 (2001) 175-179
105. van der Kolk L., Baars J., Prins M., and van Oers M. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100 (2002) 2257-2259
106. Hainsworth J., Litchy S., Burris III H., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
107. Hellerstedt B., and Ahmed A. Delayed-type hypersensitivity reaction or serum-sickness after rituximab treatment. Ann Oncol 14 (2003) 1792
108. Lowndes S., Darby A., Mead G., and Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 13 (2002) 1948-1950
109. Dereure O., Navarro R., Rossi J., and Guilhous J. Rituximab-induced vasculitis. Dermatology 203 (2001) 83-84
110. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 70 (2002) 329
111. D'Arcy C., and Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 44 (2001) 1717-1718
112. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., and Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94 (1999) 2217-2224
113. Abrams J., Lebwohl M., Guzzo C., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103 (1999) 1243-1252
114. Webb L., Walmsley M., and Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2. Eur J Immunol 26 (1996) 2320-2328
115. Kremer J., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
116. Moreland L., Alten R., van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 6 (2002) 1470-1479
117. Weinblatt M., Schiff M., Goldman M., et al. A pilot, multi-center, randomized, double-blind, placebo-controlled study of a co-stimulatory blocker CTLA4-Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis [abstract]. Arthritis Rheum 46 (2002) S204
118. Weinblatt M., Combe B., White A., Aranda R., Becker J., and Keystone E. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDS: 1-year results of the ASSURE trial [abstract]. Ann Rheum Dis 64 Suppl 111 (2005) 60
119. Nishimoto N., Yoshizaki K., Miyasaka N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 50 (2004) 1761-1769
120. Choy E., Isenberg D., Garrood T., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose escalation trial. Arthritis Rheum 46 (2002) 3143-3150
121. Maini R., Taylor P., Pavelka K., et al. Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA) [abstract]. Arthritis Rheum 48 Suppl (2003) S652
122. Issacs J., Greer S., Sharma S., et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 44 (2001) 1998-2008
123. Issacs JD, Clarke AM, Hazleman BL, et al. Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis [abstract]. Arthritis Rheum. 2004 (in press).
124. Lorenz H. T-cell-activation inhibitors in rheumatoid arthritis. Biodrugs 17 (2003) 263-270
125. Choy E., Panayi G., Emery P., et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 41 (2002) 1142-1148
126. Skov L., Kragballe K., Zachariae, et al. HuMax-CD4: A fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 139 (2003) 1433-1439
127. Kavanaugh A., Davis L., Jain R., Nichols L., Norris S., and Lipsky P. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheum 23 (1996) 1338-1344
128. Kavanaugh A., Schulze-Koops H., Davis L., and Lipsky P. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 40 (1997) 849-853
129. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov 4 (2005) 510-518
130. Ursell M., and O'Connor P. Natalizumab and other monoclonal antibodies. Neurol Clin 23 (2005) 233-246